Ember LifeSciences
Palm Beach Gardens, United States · Biotechnology, Health Care · 24 employees
Ember LifeSciences is redefining global medicine distribution through leveraging Ember’s proprietary temperature control technology to improve the way we transport life-saving medicines and vaccines around the world. Using innovative, human-centered design and an unprecedented connectivity for shippers, we aim to save lives, improve patient outcomes and reduce waste.
Funding history
- Series A — $27.0M — Mar 2026
- Series A — $16.5M — Dec 2025
- Funding Round — Undisclosed — Feb 2023
Recent signals
- Apr 29, 2026: Launched Ember LifeSciences, Inc. launched Ember Cube 2, a cold chain solution designed for transporting temperature-sensitive medicines.
- Mar 03, 2026: Raised $27.0M in Series A
- Jan 21, 2026: Ember LifeSciences Appoints Ann Hyllengren as Chief Financial Officer
- Dec 16, 2025: Raised $16.5M in Series A
- Feb 14, 2023: Raised funding in Funding Round
See plans & pricing → Track Ember LifeSciences’s funding, hiring, and signals — with verified contacts — on Fundz.